Target intelligence / Profile preview

CD47–Signal regulatory protein alpha (SIRPα) immune checkpoint interface (CD47–SIRPα)

Target
CD47–SIRPα
Molecular classification
Immune checkpoint, Receptor-ligand complex, Cell surface glycoprotein
01

Overview

The CD47–Signal regulatory protein alpha (SIRPα) immune checkpoint interface is a critical regulatory pathway of the innate immune system, often referred to as the 'don't eat me' signal. CD47 is a transmembrane protein expressed on nearly all normal cells, serving as a marker of 'self' by binding to SIRPα, an inhibitory receptor located on myeloid cells like macrophages and dendritic cells [PMID: 32103354]. This interaction leads to the phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on SIRPα, which recruits phosphatases to inhibit the pro-phagocytic activity of the macrophage [PMID: 28912440]. In oncology, many tumors overexpress CD47 to evade phagocytic clearance, making this interface a high-priority therapeutic target [PMID: 31110281]. Drugs targeting this axis, such as magrolimab and evorpacept, work by blocking the CD47-SIRPα interaction, thereby enabling macrophages to engulf and destroy cancer cells, often in synergy with other opsonizing antibodies [PMID: 34161771]. A significant challenge in targeting CD47 is its broad expression on healthy tissues, particularly red blood cells, which can lead to treatment-induced anemia and a large 'antigen sink' that complicates dosing [PMID: 33067318].

Other names
CD47-SIRPα axisDon't eat me signalIntegrin-associated protein-SIRPα interactionIAP-SIRPα interfaceCD47-SIRPalpha checkpoint
02

Mechanism of action

Blockade of the inhibitory CD47-SIRPα interaction to disrupt the 'don't eat me' signal, thereby promoting macrophage-mediated phagocytosis of target cells.

03

Biological functions

Immune evasionRegulation of phagocytosisSelf-recognitionSignal transductionMyeloid cell activation
04

Disease associations

CancerHematologic malignancyInflammationCardiovascular diseaseAtherosclerosis
05

Safety considerations

AnemiaThrombocytopeniaHemagglutinationAntigen sink effectInfusion-related reactions
06

Interacting drugs

Magrolimab

8 more in the full profile.

07

Biomarkers

CD47 expression levelSIRPα expression levelHemoglobin levelsTumor-associated macrophage (TAM) density

Beyond the preview

Go deeper on CD47–Signal regulatory protein alpha (SIRPα) immune checkpoint interface (CD47–SIRPα).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD47–Signal regulatory protein alpha (SIRPα) immune checkpoint interface (CD47–SIRPα).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call